Table 2. Univariate Cox proportional analysis of factors associated with CKD development.

	HR	95% CI	p
Age	1.052	1.020–1.084	0.001
Gender (female = 0, male = 1)	1.180	0.620–2.247	0.614
Body mass index	0.981	0.911–1.056	0.612
Diabetes mellitus (absence = 0, presence = 1)	1.423	0.750–2.699	0.280
Hypertension (absence = 0, presence = 1)	2.185	1.034–4.616	0.041
Dyslipidemia (absence = 0, presence = 1)	1.870	0.927–3.771	0.080
Past CVD events (absence = 0, presence = 1)	0.626	0.192–2.037	0.437
Ca antagonist (absence = 0, presence = 1)	1.604	0.849–3.030	0.145
ACE or ARB (absence = 0, presence = 1)	1.035	0.490–2.188	0.927
β or αβ blocker (absence = 0, presence = 1)	2.403	1.054–5.477	0.037
Diuretics (absence = 0, presence = 1)	1.978	0.607–6.439	0.257
Antiplatelet agent (absence = 0, presence = 1)	0.997	0.354–2.811	0.996
Current smoking (absence = 0, presence = 1)	1.095	0.532–2.255	0.806
eGFR	0.925	0.895–0.956	0.000
Albuminuria (absence = 0, presence = 1)	1.354	0.566–3.240	0.496
AHI	1.019	0.988–1.051	0.231
Sleep duration	0.999	0.996–1.002	0.451
Sleep efficiency	0.970	0.935–1.007	0.111
Movement index	1.015	0.995–1.034	0.137
Nocturnal SBP fall	1.013	0.971–1.057	0.553
ln (SDNN)	0.281	0.085–0.929	0.038
ln (SDANN5)	0.358	0.121–1.056	0.063
ln BDNF	0.661	0.452–0.965	0.032

Abbreviations: CVD, cardiovascular disease; eGFR, estimated glomerular filtration rate; SBP, systolic blood pressure; AHI, apnea hypopnea index; SDNN, standard deviation of NN(RR) interval; SDANN5, standard deviation of average NN(RR) interval for each 5-min period; BDNF, brain-derived neurotrophic factor